Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy
Go back to Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy| Pfizer Inc. (NYSE: PFE) | Delayed: 26.21 +0.04 (0.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.17 | 52 Week High | $37.39 | |||
| Open | $26.29 | 52 Week Low | $28.25 | |||
| Day High | $26.49 | P/E | 15.88 | |||
| Day Low | $26.11 | EPS | $1.65 | |||
| Volume | 38,762,428 | |||||
| Sangamo Biosciences, Inc. (NASDAQ: SGMO) | Delayed: 0.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.18 | 52 Week High | $9.91 | |||
| Open | $0.18 | 52 Week Low | $3.10 | |||
| Day High | $0.18 | P/E | N/A | |||
| Day Low | $0.18 | EPS | $-0.48 | |||
| Volume | 1,884,615 | |||||
